- Home
- VRAX vs GXAI Comparison
VRAX vs GXAI Comparison
Compare VRAX & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- GXAI
- Stock Information
- Founded
- VRAX 2013
- GXAI 2021
- Country
- VRAX United Kingdom
- GXAI United States
- Employees
- VRAX N/A
- GXAI N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GXAI
- Sector
- VRAX Health Care
- GXAI
- Exchange
- VRAX Nasdaq
- GXAI Nasdaq
- Market Cap
- VRAX 4.4M
- GXAI 19.7M
- IPO Year
- VRAX 2022
- GXAI 2023
- Fundamental
- Price
- VRAX $0.65
- GXAI $1.61
- Analyst Decision
- VRAX Strong Buy
- GXAI
- Analyst Count
- VRAX 1
- GXAI 0
- Target Price
- VRAX $3.00
- GXAI N/A
- AVG Volume (30 Days)
- VRAX 1.4M
- GXAI 15.2M
- Earning Date
- VRAX 01-01-0001
- GXAI 11-13-2025
- Dividend Yield
- VRAX N/A
- GXAI N/A
- EPS Growth
- VRAX N/A
- GXAI N/A
- EPS
- VRAX N/A
- GXAI N/A
- Revenue
- VRAX $6,331.00
- GXAI $198,711.00
- Revenue This Year
- VRAX $217,274.83
- GXAI N/A
- Revenue Next Year
- VRAX N/A
- GXAI N/A
- P/E Ratio
- VRAX N/A
- GXAI N/A
- Revenue Growth
- VRAX N/A
- GXAI 72158.55
- 52 Week Low
- VRAX $0.52
- GXAI $1.00
- 52 Week High
- VRAX $3.62
- GXAI $7.50
- Technical
- Relative Strength Index (RSI)
- VRAX 45.86
- GXAI 50.57
- Support Level
- VRAX $0.54
- GXAI $1.41
- Resistance Level
- VRAX $0.59
- GXAI $1.85
- Average True Range (ATR)
- VRAX 0.06
- GXAI 0.18
- MACD
- VRAX 0.01
- GXAI -0.03
- Stochastic Oscillator
- VRAX 50.76
- GXAI 21.51
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.